Researchers from Rice University and Baylor College of Medicine are hoping a first-of-its-kind “glyco-immune” checkpoint inhibitor could be the key to stopping bone cancer metastasis for breast cancer survivors. Breast cancer often migrates to other organs. As many as 40% of breast cancer survivors are diagnosed with metastatic cancer, sometimes years after their initial treatment. Bone metastasis is involved in more than two-thirds of those cases, and bone metastatic lesions are known to “seed”...